About Medannex limited

About company

Medannex is an award-winning clinical-stage Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. “MDX-124 could provide a new treatment option as a single agent or in combination with established cancer therapies, and clinical trials are now eagerly anticipated.” Professor Daniel Palmer,Department of Molecular & Clinical Cancer Medicine,University of Liverpool Our